News articles about DexCom (NASDAQ:DXCM) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. DexCom earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the medical device company an impact score of 47.1696790251564 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- DexCom, Inc. (DXCM) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- DexCom (DXCM) versus Cytori Therapeutics (CYTX) Critical Review (americanbankingnews.com)
- DexCom, Inc. (DXCM) Lowered to “D+” at TheStreet (americanbankingnews.com)
- ETFs with exposure to DexCom, Inc. : October 27, 2017 (finance.yahoo.com)
- Head-To-Head Comparison: DexCom (DXCM) and Its Rivals (americanbankingnews.com)
DexCom (NASDAQ:DXCM) opened at 44.97 on Wednesday. DexCom has a 1-year low of $42.62 and a 1-year high of $88.80. The stock’s market capitalization is $3.89 billion. The stock’s 50 day moving average price is $54.18 and its 200 day moving average price is $67.68.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The firm had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. During the same period last year, the company earned ($0.24) EPS. DexCom’s quarterly revenue was up 24.3% compared to the same quarter last year. On average, equities research analysts predict that DexCom will post ($0.80) earnings per share for the current fiscal year.
A number of analysts have recently issued reports on the company. Canaccord Genuity reiterated a “buy” rating and set a $90.00 price target on shares of DexCom in a research report on Tuesday, August 22nd. ValuEngine upgraded DexCom from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub upgraded DexCom from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Barclays PLC assumed coverage on DexCom in a research report on Friday, September 15th. They set an “equal weight” rating and a $76.00 price target for the company. Finally, Cowen and Company reiterated a “buy” rating and set a $90.00 price target on shares of DexCom in a research report on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $72.19.
WARNING: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.com-unik.info/2017/11/01/dexcom-dxcm-earning-somewhat-positive-press-coverage-report-shows.html.
In other DexCom news, EVP Andrew K. Balo sold 3,244 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $71.18, for a total transaction of $230,907.92. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Richard Doubleday sold 1,635 shares of the firm’s stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $44.82, for a total value of $73,280.70. Following the transaction, the executive vice president now owns 65,049 shares in the company, valued at $2,915,496.18. The disclosure for this sale can be found here. Insiders have sold a total of 23,208 shares of company stock worth $1,597,567 over the last 90 days. 1.70% of the stock is currently owned by company insiders.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
What are top analysts saying about DexCom Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DexCom Inc. and related companies.